Literature DB >> 29393522

Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans.

Kelly R Reveles1,2,3, Eric M Mortensen4,5, Jim M Koeller1,2, Kenneth A Lawson1, Mary Jo V Pugh3,6, Sarah A Rumbellow1,2, Jacqueline R Argamany1,2, Christopher R Frei1,2,3.   

Abstract

STUDY
OBJECTIVE: Prior studies have identified risk factors for recurrent Clostridium difficile infection (CDI), but few studies have integrated these factors into a clinical prediction rule that can aid clinical decision-making. The objectives of this study were to derive and validate a CDI recurrence prediction rule to identify patients at risk for first recurrence in a national cohort of veterans.
DESIGN: Retrospective cohort study. DATA SOURCE: Veterans Affairs Informatics and Computing Infrastructure. PATIENTS: A total of 22,615 adult Veterans Health Administration beneficiaries with first-episode CDI between October 1, 2002, and September 30, 2014; of these patients, 7538 were assigned to the derivation cohort and 15,077 to the validation cohort.
MEASUREMENTS AND MAIN RESULTS: A 60-day CDI recurrence prediction rule was created in a derivation cohort using backward logistic regression. Those variables significant at p<0.01 were assigned an integer score proportional to the regression coefficient. The model was then validated in the derivation cohort and a separate validation cohort. Patients were then split into three risk categories, and rates of recurrence were described for each category. The CDI recurrence prediction rule included the following predictor variables with their respective point values: prior third- and fourth-generation cephalosporins (1 point), prior proton pump inhibitors (1 point), prior antidiarrheals (1 point), nonsevere CDI (2 points), and community-onset CDI (3 points). In the derivation cohort, the 60-day CDI recurrence risk for each score ranged from 7.5% (0 points) to 57.9% (8 points). The risk score was strongly correlated with recurrence (R2  = 0.94). Patients were split into low-risk (0-2 points), medium-risk (3-5 points), and high-risk (6-8 points) classes and had the following recurrence rates: 8.9%, 20.2%, and 35.0%, respectively. Findings were similar in the validation cohort.
CONCLUSION: Several CDI and patient-specific factors were independently associated with 60-day CDI recurrence risk. When integrated into a clinical prediction rule, higher risk scores and risk classes were strongly correlated with CDI recurrence. This clinical prediction rule can be used by providers to identify patients at high risk for CDI recurrence and help guide preventive strategy decisions, while accounting for clinical judgment.
© 2018 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  zzm321990Clostridium difficilezzm321990; epidemiology; prediction rule

Mesh:

Year:  2018        PMID: 29393522      PMCID: PMC5867250          DOI: 10.1002/phar.2088

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  28 in total

1.  Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.

Authors:  Chun Shing Kwok; Aaron Kobina Arthur; Chukwudubem Ifeanyichukwu Anibueze; Sonal Singh; Rodrigo Cavallazzi; Yoon Kong Loke
Journal:  Am J Gastroenterol       Date:  2012-04-24       Impact factor: 10.864

2.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

3.  The prediction of complicated Clostridium difficile infections in children.

Authors:  Sarah Tschudin-Sutter; Pranita D Tamma; Aaron M Milstone; Trish M Perl
Journal:  Infect Control Hosp Epidemiol       Date:  2014-05-20       Impact factor: 3.254

Review 4.  Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  Abhishek Deshpande; Vinay Pasupuleti; Priyaleela Thota; Chaitanya Pant; David D K Rolston; Adrian V Hernandez; Curtis J Donskey; Thomas G Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2015-01-28       Impact factor: 3.254

5.  Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis.

Authors:  Dalila Martínez; Gustavo Heudebert; Carlos Seas; German Henostroza; Martin Rodriguez; Carlos Zamudio; Robert M Centor; Cesar Herrera; Eduardo Gotuzzo; Carlos Estrada
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

Review 6.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Authors:  Stuart Johnson
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

7.  Development and validation of a recurrent Clostridium difficile risk-prediction model.

Authors:  Marya D Zilberberg; Kimberly Reske; Margaret Olsen; Yan Yan; Erik R Dubberke
Journal:  J Hosp Med       Date:  2014-04-04       Impact factor: 2.960

Review 8.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

9.  Predictors of first recurrence of Clostridium difficile infection: implications for initial management.

Authors:  David W Eyre; A Sarah Walker; David Wyllie; Kate E Dingle; David Griffiths; John Finney; Lily O'Connor; Alison Vaughan; Derrick W Crook; Mark H Wilcox; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis.

Authors:  Christoph Lübbert; Lisa Zimmermann; Julia Borchert; Bernd Hörner; Reinier Mutters; Arne C Rodloff
Journal:  Infect Dis Ther       Date:  2016-10-21
View more
  10 in total

Review 1.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

2.  Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation.

Authors:  Ghadeer K Dawwas; Colleen M Brensinger; Ravy K Vajravelu; Qufei Wu; Colleen R Kelly; Loren Laine; Gary D Wu; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-08       Impact factor: 11.382

3.  A possible association between statin use and improved Clostridioides difficile infection mortality in veterans.

Authors:  Jacqueline R Argamany; Grace C Lee; Bryson D Duhon; Amina R Zeidan; Eric H Young; Kelly R Reveles
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

Review 4.  Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI.

Authors:  I Castro; M Tasias; E Calabuig; M Salavert
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553

5.  Efficacy of prolonged tapered and pulsed vancomycin regimen on recurrent Clostridioides difficile infection in the Japanese setting: a case control study.

Authors:  Takumi Umemura; Aiko Ota; Yoshikazu Mutoh; Chihiro Norizuki; Takahito Mizuno; Koji Kozaki; Yoshiaki Ikeda; Toshihiko Ichihara
Journal:  J Pharm Health Care Sci       Date:  2019-08-08

6.  Neighborhood disadvantage and 30-day readmission risk following Clostridioides difficile infection hospitalization.

Authors:  Elizabeth Scaria; W Ryan Powell; Jen Birstler; Oguzhan Alagoz; Daniel Shirley; Amy J H Kind; Nasia Safdar
Journal:  BMC Infect Dis       Date:  2020-10-16       Impact factor: 3.090

7.  External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection.

Authors:  Tessel M van Rossen; Laura J van Dijk; Martijn W Heymans; Olaf M Dekkers; Christina M J E Vandenbroucke-Grauls; Yvette H van Beurden
Journal:  Therap Adv Gastroenterol       Date:  2021-01-09       Impact factor: 4.409

8.  The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts.

Authors:  Ronald G Hall; Travis J Cole; Chip Shaw; Carlos A Alvarez
Journal:  Antibiotics (Basel)       Date:  2022-02-23

9.  Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID).

Authors:  Kerrie Davies; Jody Lawrence; Claire Berry; Georgina Davis; Holly Yu; Bing Cai; Elisa Gonzalez; Ida Prantner; Andrea Kurcz; Ioana Macovei; Hanna Pituch; Elena Nováková; Otakar Nyč; Barbara Gärtner; Fabian K Berger; Monica Oleastro; Oliver A Cornely; Maria J G T Vehreschild; Louise Pedneault; Mark Wilcox
Journal:  Front Public Health       Date:  2020-07-17

10.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.